ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

ClinicalTrials.gov ID: NCT05256745

Public ClinicalTrials.gov record NCT05256745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer

Study identification

NCT ID
NCT05256745
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Georgetown University
Other
Enrollment
48 participants

Conditions and interventions

Interventions

  • Chemotherapy regimen that includes ddAC Drug
  • TC Drug
  • TCHP Drug
  • TTP488 Drug
  • ddAC/ddT Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 5, 2023
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026
Last update posted
Dec 23, 2025

2023 – 2026

United States locations

U.S. sites
3
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Georgetown Lombardi Comprehensive Cancer Center Washington D.C. District of Columbia 20007 Recruiting
Medstar Washington Hospital Center Washington D.C. District of Columbia 20010 Recruiting
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05256745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 23, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05256745 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →